Ticker Details
Summit Therapeutics Inc. Common Stock Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
IPO Date:	April 1, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$10.5B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 4.16%
Avg Daily Range (30 D):	$0.45 | 3.25%
Avg Daily Range (90 D):	$0.60 | 3.51%

Institutional Daily Volume
Avg Daily Volume:	1.17M
Avg Daily Volume (30 D):	3.89M
Avg Daily Volume (90 D):	4.61M

Trade Size
Avg Trade Size (Sh.):	131
Avg Trade Size (Sh.) (30 D):	95
Avg Trade Size (Sh.) (90 D):	98

Institutional Trades
Total Institutional Trades:	1,895
Avg Institutional Trade:	$3.14M
Avg Institutional Trade (30 D):	$2.77M
Avg Institutional Trade (90 D):	$2.85M
Avg Institutional Trade Volume:	.2M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.89M
Avg Closing Trade (30 D):	$7.2M
Avg Closing Trade (90 D):	$8.3M
Avg Closing Volume:	397.4K

News

Jun 10, 2026 @ 5:13 PM Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot... Source: Piero Cingari

May 23, 2026 @ 10:13 PM Why a Biotech Fund Opened a New $6 Million Positio... Source: Jonathan Ponciano

May 3, 2026 @ 1:16 PM Roblox, Spotify, And Robinhood Are Among Top 10 La... Source: Nabaparna Bhattacharya

May 1, 2026 @ 5:11 PM Stock Market Today: Apple Earnings Power S&P 500, ... Source: Piero Cingari

Apr 19, 2026 @ 2:01 PM IonQ, Oklo, And Robinhood Are Among the Top 10 Lar... Source: Nabaparna Bhattacharya

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.11	$-.28	$-.24
Diluted EPS	$-1.11	$-.28	$-.24
Revenue
Gross Profit
Net Income / Loss	$-856.09M	$-215.7M	$-189.42M
Operating Income / Loss
Cost of Revenue
Net Cash Flow	$121.51M
PE Ratio